Astellas Pharma revenue and financials

4503 · TSE · JPY

¥2,255.50+0.53%+¥12.00

Close · October 7, 2026

In the fiscal year ended March 2026, Astellas Pharma reported revenue of ¥2.14T (+11.87% year over year). Net income was ¥291.54B, a net margin of 13.6%.

Annual revenue · 2026: ¥2.14T

¥1.52T2023
¥1.6T2024
¥1.91T2025
¥2.14T2026

Fiscal year ending in March. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +11.87%; FY to Mar 2026 vs FY to Mar 2025
Net income growth: +474.49%; FY to Mar 2026 vs FY to Mar 2025
Net margin: 13.6%; FY to Mar 2025: 2.7%

Financial data

Amounts in millions of JPY; per-share values in JPY; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q2 2025
Basic EPS	79.15	38.22
Diluted EPS	78.96	38.11
Average shares (basic)	1,792	1,790
Average shares (diluted)	1,796	1,795